Harvard Bioscience, Inc. (HBIO) Receives Average Recommendation of “Strong Buy” from Analysts
Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus target price of $5.50 for the company and are predicting that the company will post $0.05 EPS for the current quarter, according to Zacks. Zacks has also given Harvard Bioscience an industry rank of 46 out of 265 based on the ratings given to its competitors.
Large investors have recently added to or reduced their stakes in the company. New York State Common Retirement Fund bought a new stake in shares of Harvard Bioscience in the 3rd quarter valued at about $321,000. Northern Trust Corp boosted its holdings in shares of Harvard Bioscience by 5.2% in the 2nd quarter. Northern Trust Corp now owns 86,205 shares of the medical instruments supplier’s stock valued at $220,000 after buying an additional 4,260 shares in the last quarter. Algert Global LLC boosted its holdings in shares of Harvard Bioscience by 31.0% in the 3rd quarter. Algert Global LLC now owns 149,094 shares of the medical instruments supplier’s stock valued at $559,000 after buying an additional 35,276 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Harvard Bioscience in the 2nd quarter valued at about $752,000. Finally, Granahan Investment Management Inc. MA boosted its holdings in shares of Harvard Bioscience by 80.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 537,467 shares of the medical instruments supplier’s stock valued at $2,016,000 after buying an additional 240,055 shares in the last quarter. Institutional investors and hedge funds own 61.68% of the company’s stock.
Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.03 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.03. Harvard Bioscience had a negative net margin of 3.16% and a positive return on equity of 1.11%. The business had revenue of $25.05 million for the quarter, compared to analysts’ expectations of $24.60 million. research analysts forecast that Harvard Bioscience will post 0.05 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/06/harvard-bioscience-inc-hbio-receives-average-recommendation-of-strong-buy-from-analysts.html.
About Harvard Bioscience
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.